Literature DB >> 9624508

Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis.

M Fernandez1, M E Hickman, C J Baker.   

Abstract

In vitro testing of 229 group B streptococcal isolates from a variety of patients with invasive infections indicated uniform penicillin G susceptibility. However, 17 (7.4%) isolates were resistant to erythromycin and 8 (3.4%) were resistant to clindamycin. These results support the continued use of penicillin G as the drug of choice for the treatment and prevention of group B streptococcal disease.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9624508      PMCID： PMC105636     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Susceptibility of hemolytic streptococci, other than those of group D, to eleven antibiotics in vitro.

Authors:  W F JONES; H A FELDMAN; M FINLAND
Journal:  Am J Clin Pathol       Date:  1957-02       Impact factor: 2.493

2.  Change in susceptibility of group B streptococci to penicillin G from 1968 through 1975.

Authors:  M J Severin; J L Wiley
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

3.  Susceptibility to six antibiotics of group B streptococci isolated from cerebrospinal fluid.

Authors:  C Mulder; P Bol; A Nabbe; B Zanen
Journal:  Scand J Infect Dis       Date:  1985

4.  Antimicrobial susceptibility of GBS.

Authors:  K S Kim
Journal:  Antibiot Chemother (1971)       Date:  1985

5.  Antibiotic resistance patterns of group B streptococci in pregnant women.

Authors:  K Berkowitz; J A Regan; E Greenberg
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

6.  Antibiotic resistance and penicillin tolerance in clinical isolates of group B streptococci.

Authors:  C Betriu; M Gomez; A Sanchez; A Cruceyra; J Romero; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

7.  Synergism, killing kinetics, and antimicrobial susceptibility of group A and B streptococci.

Authors:  C N Baker; C Thornsberry; R R Facklam
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

8.  Invasive group B streptococcal disease: the emergence of serotype V.

Authors:  H M Blumberg; D S Stephens; M Modansky; M Erwin; J Elliot; R R Facklam; A Schuchat; W Baughman; M M Farley
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

9.  Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP Working Group.

Authors:  D B Jernigan; M S Cetron; R F Breiman
Journal:  JAMA       Date:  1996-01-17       Impact factor: 56.272

10.  Prevention of perinatal group B streptococcal disease: a public health perspective. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1996-05-31
View more
  28 in total

1.  High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan.

Authors:  P R Hsueh; L J Teng; L N Lee; S W Ho; P C Yang; K T Luh
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  Prevention of group B streptococcal infection in newborns: recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

3.  Mechanisms of macrolide resistance in clinical group B streptococci isolated in France.

Authors:  F Fitoussi; C Loukil; I Gros; O Clermont; P Mariani; S Bonacorsi; I Le Thomas; D Deforche; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Prevention of group B streptococcal infection in newborns. Recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  Can Fam Physician       Date:  2002-05       Impact factor: 3.275

5.  A serotype V clone is predominant among erythromycin-resistant Streptococcus agalactiae isolates in a southwestern region of Germany.

Authors:  Ulrich von Both; Michael Ruess; Urban Mueller; Kirsten Fluegge; Anna Sander; Reinhard Berner
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

6.  Genetic basis of antibiotic resistance in Streptococcus agalactiae strains isolated in a French hospital.

Authors:  Claire Poyart; Laurence Jardy; Gilles Quesne; Patrick Berche; Patrick Trieu-Cuot
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

7.  Antimicrobial susceptibilities of group B streptococci in New Zealand.

Authors:  Anja M Werno; Trevor P Anderson; David R Murdoch
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 8.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

9.  Heterogeneity of genotype-phenotype correlation among macrolide-resistant Streptococcus agalactiae isolates.

Authors:  Ulrich von Both; Anna Buerckstuemmer; Kirsten Fluegge; Reinhard Berner
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

10.  Pharmacokinetics of penicillin g in very-low-birth-weight neonates.

Authors:  Tuuli Metsvaht; Kersti Oselin; Mari-Liis Ilmoja; Kaili Anier; Irja Lutsar
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.